table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 all comersCOVID-19 mild to moderate
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderate
neutralizing antibody ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-3 ...
bamlanivimab monotherapy ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve) RECOVERY ... Somersan-Karakaya ... Suzuki
cilgavimab and tixagevimab (Evusheld) ACTIV-3/TICO ... Chen
sotrovimab (Xevudy; VIR-7831) ACTIV-3/ TICO ...

0 studies excluded by filtering options 2

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons